News

Recommended tags

+ More Filters

Indication

Solid Tumors ^× Lung Cancer Prostate Cancer Ovarian Cancer

Product Candidates

BOXR1030 DCVAC/LuCa DCVAC/OvCa DCVAC/PCa nanrilkefusp alfa SOT102 ^× SOT106 SOT109 SOT201

Release Type

Corporate Investments ^× Partnering

NEWS October 16, 2023

SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need.
Collaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors.
Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million.

NEWS December 2, 2021

SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline

PPF Group provides funding to advance SOTIO through key clinical milestones
Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial
Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.

NEWS October 20, 2016

SOTIO and NBE-Therapeutics sign collaboration and license agreement for next-generation antibody-drug conjugates

Basel, Switzerland & Prague, Czech Republic – NBE-Therapeutics AG and SOTIO a.s. today announced that the companies have entered into a collaboration for the development of next-generation antibody-drug conjugates (ADCs) for improved cancer therapy. Under the agreement, NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products will be based on NBE’s proprietary antibody discovery and conjugation platforms, including NBE’s Transpo-mAb^TM antibody platform, its site-specific SMAC^TM conjugation technology and its novel ultra-potent toxin platform. SOTIO will have global responsibility for clinical development, registration and commercialization of the ADC products.

Cookie name	Description	Expiration
BCAPPSESSID3	The BCAPPSESSID3 cookie is native to PHP and enables websites to store serialised state data. It is used to establish a user session and to pass state data via a temporary cookie, which is commonly referred to as a session cookie.	14 days
SSC_COOKIE_*	This cookie stores your decision regarding the storage of cookies in your browser.	2 years

Cookie name	Description	Expiration
_ga	The GA cookie is set, when a person visits your website for the first time. Google Analytics sends the client ID with each hit in order to associate hits with a user. A GA cookie can exist only on the device and browser where it has been set.	2 years
_gid	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing.	24 hours
_gat_gtag_UA_27872723_1	This cookie is used to throttle request rate. These are third party cookies that are placed on your device to allow us to use the Google Analytics service. These cookies are used to collect information about how visitors use our website. We use this information to compile reports and to help us improve the website.	Immediately
AW_VISITOR	Performance cookie to analyze traffic.	1 year

Your privacy

Strictly necessary cookies

Performance cookies

Functional cookies

Targeting and Advertising cookies

More information about Cookies